Focusing on investing in medical innovations for a healthier future, Recordati continues to operate in the field of common and rare diseases in approximately 150 countries. For Recordati’s success story, we interviewed Erdem Çınar, Vice President of Recordati Group, Regional President for Middle East, Africa, General Manager of Recordati Türkiye.
1. Could you inform us about Recordati, which has been at the forefront of medicines that improve and change lives for 100 years?
With its beginnings in a pharmacy in Italy in the 1920s, Recordati is now an international pharmaceutical group, listed on the Italian stock exchange, with over 4,300 employees. We are a group of employees focused on investing in medical innovations that bring a healthier future, who go to extraordinary lengths for helping people all around the world with our stakeholders. As Recordati, we operate in the fields of across specialty and primary care, consumer healthcare, and rare diseases in approximately 150 countries across EMEA (Europe, Middle East, Africa), Americas and APAC (Asia, Pacific) regions of the world.
In line with this focus we have adopted as Recordati, we have entered the Turkish healthcare sector by acquiring two local pharmaceutical companies since 2008. We continue our operations in Turkey with our head office, plant and extensive sales force team. With our 80 million box capacity production facility and 41 different products and treatment options, we continue our activities and investments in the pharmaceutical industry without slowing down.
“WE ARE AT THE FRONT LINE OF SUPPORTING PATIENTS”
- You develop medicines that will serve people living with many different diseases. What about the diseases you deal with in this context?
We bring treatment options in 2 main areas: common diseases and rare diseases and in many therapeutic areas. In this direction, for over 20 years we have been at the forefront of supporting patients with cardiovascular disease with a wide portfolio of products and services in primary and secondary care.
We are a recognised partner in Urology, providing therapeutic solutions for both men’s and women’s health including prostate cancer, benign prostatic hyperplasia (BPH), over-active bladder (OAB) and infection related diseases.) and infection related diseases.
We have a diversified portfolio of prescription and self-medication solutions for the diagnosis and treatment of diseases which affect the upper and lower gastrointestinal tract. We have a large portfolio of prescription and self-medication treatments to promote respiratory health including asthma and symptoms associated with cough and cold.
Recordati Rare Diseases business unit has focused on some of the rare cancers for which there are few treatment options in both adult and paediatric indications, as well as metabolic diseases, many of which are difficult to diagnose and can be life-threatening.
“A MORAL RESPONSIBILITY RATHER THAN A COMPANY LIABILITY”
3. How does Recordati approach the issue of sustainability?
At Recordati, we prioritise five areas in our sustainability plan: patient care, people care, environmental protection, responsible sourcing, ethics and integrity.
We have a long history of entrepreneurial passion and a strong reputation and a desire to continue growing and creating value in an ethical, enduring, and sustainable way, all while respecting the laws and regulations that apply in the countries where we operate, protecting people and the environment, and supplying safe, high-quality products.
For instance ,approximately 84% purchased electricity from renewable sources for the Group’s plants and annexed offices. Solar panels installed at the production plants in Ireland and Spain. Approximately 7,500 trees planted in 2021 and 2022, in the metropolitan area of Milan with a commitment to plant 11,250 trees by 2023. We believe that these projects are an essential part of a growing business, but also support and develop the community in which it operates and make its employees proud.
“WE HAVE ANOTHER NEW PRODUCTION LINE PROJECT”
- Could you tell us about the equipment and capacity of your facility in detail?
Recordati has seven industrial plants and two chemical plants all over the world. In addition to these facilities, we also have a specialised packaging and distribution centre for rare diseases.
In Turkey, we have a manufacturing facility with a capacity of 80 million boxes drugs, located in the Tekirdağ Çerkezköy Organized Industrial Zone, which started operations in 2016 with an investment of approximately 50 million dollars and almost all of our production is made in Türkiye. The facility also has sufficient capacity for contract manufacturing of solid, semi-solid, and liquid drugs for oral use.
In addition to these, we have a new production line project. For this project, we plan to invest in machinery and equipment as well as an additional investment to expand the storage area. With these investments, we will achieve a total production capacity increase of 11.3%. The majority of the products produced on this line will be exported.
